Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Disease
Details : Ctexli (chenodiol) is an oral cholesterol synthesis inhibitor which is being evaluated for the treatment of cerebrotendinous xanthomatosis.
Product Name : Ctexli
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2025
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
Details : Chenodal (chenodeoxycholic acid) is an oral cholesterol synthesis inhibitor which is being evaluated for the treatment of cerebrotendinous xanthomatosis.
Product Name : Chenodal
Product Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2024
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Chenodiol (chenodiol) tablets is a naturally occurring bile acid, which is investigated for the treatment of adult patients with cerebrotendinous xanthomatosis.
Product Name : Chenodal
Product Type : Small molecule
Upfront Cash : Not Applicable
October 02, 2023
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable